Radiation and Checkpoint Inhibitor Immunotherapy Lead to Long Term Disease Control in a Metastatic RCC patient With Brain Metastases

Renal cell carcinoma (RCC) comprises 4.2% of all new cancer cases in the United States and 30% of cases are metastatic (mRCC) at diagnosis. Brain metastatic RCC historically has poor prognosis, but the development of immune checkpoint inhibitors has revolutionized their care and may be successfully...

Descripción completa

Detalles Bibliográficos
Autores principales: Levitin, Maria, Ofori, Joel, Shin, Woo Jae, Huang, Jiayi, Daly, Mackenzie, Cao, Dengfeng, Pachynski, Russell
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539115/
https://www.ncbi.nlm.nih.gov/pubmed/33072598
http://dx.doi.org/10.3389/fonc.2020.566070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539115/
https://www.ncbi.nlm.nih.gov/pubmed/33072598
http://dx.doi.org/10.3389/fonc.2020.566070

Ejemplares similares